Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:CSCI - Post by User

Comment by prophetoffactzon Oct 04, 2024 9:35am
63 Views
Post# 36253021

RE:Why no sharebuyback??

RE:Why no sharebuyback??
Stinzo wrote: Company holds more cash then market valuation, that's assuming physical assets are worth 0.

Shareholders desperately need some breathing air. 

It seems to me to be a no brainer, use a few M to buy some shares and build some credibility ...


The company is losing significant money. A lot rode on the pediatric diagnostic trial which could have provided substantial upfront, milestone and royalty payments as they drive to sustainability. Buying stock doesn't create a sustainable business and significant funds may be needed for the new plan to sustainability. We need to see the plan to sustainability which could take some time meaning more cash burn.

News release:  


Mr. Gagnon added, “The reason for creating COSCIENS and the stated goals of the Aeterna Zentaris (now COSCIENS) and Ceapro combination was, and remains:

  • broadening the revenue base, product offering and pipeline;
  • evaluating our combined product portfolio in an effort to create a mix of near-term revenue generating products with longer term, potentially higher reward products, while also diversifying our respective risks;
  • right-sizing our administrative costs and prioritize capital with a clear focus on products and programs that have the best chance to succeed and create value inflection points; and
  • taking steps to recruit future leadership talent and expertise to execute on our strategy and take COSCIENS to the next level.

The first two goals will take time to achieve  – we want to ensure that we are looking at comprehensive data and market information when making key product related decisions. We also want to ensure that the next President and CEO will have a voice in key decisions as they chart the future direction of COSCIENS.”

 

 

<< Previous
Bullboard Posts
Next >>